Filtering by:
Soft Tissue SarcomaTop Story
January 24, 2020
FDA Approves Tazverik (Tazemetostat) for Epithelioid Sarcoma
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
November 28, 2018
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
July 5, 2018
Liposarcoma Survivor Shares Story to Inspire Hope
When soft tissue sarcoma survivor Apreal Cloutier first noticed a lump on the back of her thigh in late 2015, she had no idea it might be cancer.